Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis.
breast cancer
cathepsin D
disease-free survival
meta-analysis
overall survival
prognostic biomarker
systematic review
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
11
2019
accepted:
27
04
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
20
6
2020
Statut:
epublish
Résumé
High cathepsin D has been associated with poor prognosis in breast cancer; however, the results of many studies are controversial. Here, we assessed the association between high cathepsin D levels and worse breast cancer prognosis by conducting a meta-analysis. A comprehensive search strategy was used to search relevant literature in PUBMED and EMBASE by September 2018. The meta-analysis was performed in Review Manager 5.3 using hazard ratios (HRs) with 95% confidence intervals (CIs). A total of 15,355 breast cancer patients from 26 eligible studies were included in this meta-analysis. Significant associations between elevated high cathepsin D and poor overall survival (OS) (HR = 1.61, 95% CI: 1.35-1.92, Our meta-analysis suggests that high expression levels of cathepsin D are associated with a poor prognosis in breast cancer. Based on our subgroup analysis, we believe that cathepsin D can act as a marker for poor breast cancer prognosis and also as a therapeutic target for breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
High cathepsin D has been associated with poor prognosis in breast cancer; however, the results of many studies are controversial. Here, we assessed the association between high cathepsin D levels and worse breast cancer prognosis by conducting a meta-analysis.
METHODS
METHODS
A comprehensive search strategy was used to search relevant literature in PUBMED and EMBASE by September 2018. The meta-analysis was performed in Review Manager 5.3 using hazard ratios (HRs) with 95% confidence intervals (CIs).
RESULTS
RESULTS
A total of 15,355 breast cancer patients from 26 eligible studies were included in this meta-analysis. Significant associations between elevated high cathepsin D and poor overall survival (OS) (HR = 1.61, 95% CI: 1.35-1.92,
CONCLUSIONS
CONCLUSIONS
Our meta-analysis suggests that high expression levels of cathepsin D are associated with a poor prognosis in breast cancer. Based on our subgroup analysis, we believe that cathepsin D can act as a marker for poor breast cancer prognosis and also as a therapeutic target for breast cancer.
Identifiants
pubmed: 32550865
doi: 10.1177/1758835920927838
pii: 10.1177_1758835920927838
pmc: PMC7281710
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920927838Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Biochim Biophys Acta Mol Cell Res. 2018 Jan;1865(1):25-33
pubmed: 29024694
J Res Med Sci. 2013 Apr;18(4):283-90
pubmed: 24124424
Cancer Lett. 1996 Feb 6;99(2):233-8
pubmed: 8616829
Biomark Med. 2013 Oct;7(5):747-58
pubmed: 24044567
Br J Cancer. 1999 Apr;80(1-2):167-74
pubmed: 10389993
Endocrinology. 1986 Apr;118(4):1537-45
pubmed: 3948791
J Surg Oncol. 2011 Jun;103(8):746-50
pubmed: 21544817
Ann Intern Med. 2011 Feb 15;154(4):253-9
pubmed: 21320940
J Surg Oncol. 2012 May;105(6):577-85
pubmed: 22065549
Br J Cancer. 1999 May;80(3-4):419-26
pubmed: 10408848
BMC Cancer. 2018 Aug 24;18(1):850
pubmed: 30143015
Breast Cancer Res Treat. 1995;33(2):137-45
pubmed: 7749141
Am J Pathol. 1992 Nov;141(5):1003-12
pubmed: 1332483
Clin Chem. 1992 Oct;38(10):2114-6
pubmed: 1395002
Breast Cancer Res Treat. 1991 Oct;19(2):85-93
pubmed: 1756272
Eur J Cancer. 1994;30A(14):2042-8
pubmed: 7857700
Ann Oncol. 2011 Jan;22(1):17-23
pubmed: 20566473
Eur J Cancer. 1991;27(8):970-2
pubmed: 1832905
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Oncogene. 2002 Aug 29;21(38):5951-5
pubmed: 12185597
Oncol Lett. 2016 Jan;11(1):575-583
pubmed: 26870250
PLoS One. 2013 Dec 10;8(12):e83081
pubmed: 24340082
J Cell Biol. 2005 Jan 31;168(3):489-99
pubmed: 15668295
N Engl J Med. 1987 Feb 19;316(8):450-5
pubmed: 3807986
J Immunother Cancer. 2019 Feb 4;7(1):29
pubmed: 30717773
Br J Cancer. 1993 Apr;67(4):767-72
pubmed: 8471433
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Biol Ther. 2011 Jan 15;11(2):277-83
pubmed: 21263214
Cancer. 1993 Mar 15;71(6):2006-12
pubmed: 8443752
J Natl Compr Canc Netw. 2013 Mar 1;11(3):246-50; quiz 251
pubmed: 23486451
Ann Surg. 2002 Jan;235(1):10-26
pubmed: 11753038
Int J Biol Markers. 2005 Apr-Jun;20(2):103-11
pubmed: 16011040
Yonsei Med J. 2018 Jun;59(4):495-500
pubmed: 29749132
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Cancer Treat Rev. 2014 Apr;40(3):434-44
pubmed: 24138841
Oncogene. 2002 Aug 1;21(33):5127-34
pubmed: 12140763
PLoS One. 2018 Aug 7;13(8):e0201844
pubmed: 30086159
Cancer Med. 2014 Feb;3(1):134-42
pubmed: 24407937
Oncol Lett. 2011 Nov;2(6):1183-1190
pubmed: 22848286
Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28
pubmed: 18396408
Cancer Res. 1995 Aug 1;55(15):3331-8
pubmed: 7614468
Cancer. 1993 May 1;71(9):2756-63
pubmed: 8385566
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Clin Oncol. 1993 Jan;11(1):36-43
pubmed: 8093367
Int J Rad Appl Instrum B. 1987;14(4):377-84
pubmed: 3654255
Biol Res. 2017 Oct 2;50(1):33
pubmed: 28969709
Breast Cancer Res Treat. 2017 Oct;165(3):709-720
pubmed: 28677011
Eur J Cancer. 2000 Jul;36(11):1374-80
pubmed: 10899650
Mol Cancer Res. 2005 Apr;3(4):203-18
pubmed: 15831674
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Lett. 2006 Jun 18;237(2):167-79
pubmed: 16046058
Int J Cancer. 1993 Sep 30;55(3):429-35
pubmed: 8397164
J Clin Oncol. 2016 Jul 10;34(20):2416-27
pubmed: 27091714
Br J Cancer. 1999 Jan;79(2):300-7
pubmed: 9888472
Clin Breast Cancer. 2017 Jun;17(3):e119-e125
pubmed: 28017540
Cell Mol Gastroenterol Hepatol. 2017 Dec 15;5(4):630-633.e1
pubmed: 29930983
Biomol Ther (Seoul). 2012 May;20(3):256-67
pubmed: 24130921
Cancers (Basel). 2019 Mar 06;11(3):
pubmed: 30845739
Br J Cancer. 1995 Jan;71(1):155-9
pubmed: 7819033
Cytometry B Clin Cytom. 2004 May;59(1):24-31
pubmed: 15108167